| Aktie | Ticker | Breite | GCS | 2025/Q3 | |||
|---|---|---|---|---|---|---|---|
| Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | ||||
| 30.933.557 $ | +5.390.355 $ | +15,4 % | 4 | ||||
| Taysha Gene Therapies, Inc. | TSHA | → 0 | Schwach | 12.099.000 $ | +2.639.550 $ | +27,9 % | 1 |
| Forte Biosciences, Inc. | FBRX | → 0 | Schwach | 11.799.705 $ | +1.628.359 $ | +16,0 % | 1 |
| ALUMIS INC. | ALMS | → 0 | Neutral | 5.583.008 $ | +1.385.258 $ | +33,0 % | 1 |
| Zentalis Pharmaceuticals, Inc. | ZNTL | → 0 | Schwach | 1.451.844 $ | -262.812 $ | -15,3 % | 1 |
| 30.933.557 $ | +5.390.355 $ | +15,4 % | 4 | ||||